JUBLPHARMA : JBI-802 PHASE 1 DATA SELECTED FOR ORAL

JUBLPHARMA : JBI-802 PHASE 1 DATA SELECTED FOR ORAL PRESENTATION AT ASH 2026 JUBLPHARMA • Preliminary Phase 1/2 data for JBI-802, a first-in-class oral dual LSD1/HDAC6 inhibitor, picked for oral presentation at the 68th ASH Annual Meeting (December 12-15, 2026) • All 8 patients who started at 15 mg achieved over 50% platelet reduction or platelet normalization by Week 3, with median time to response of 15 days • Platelet normalization maintained through 33, 44 and 46 weeks in 15 mg patients with more than 12 weeks of follow-up • Seven of 11 patients with leukocytosis at 15 mg achieved a complete hematologic response • No dose-limiting toxicities observed at 5, 7 or 15 mg; data cut-off June 30, 2026 • JBI-802 is being studied in essential thrombocythemia, polycythemia vera and MDS/MPN; Jubilant Therapeutics is a step-down subsidiary of Jubilant Pharmova Impact: Positive (Early-stage clinical validation of the lead asset in thrombocytosis-predominant MPNs; ASH oral slot improves visibility, though data remain preliminary from a small patient set)